The Association of Molecular Biomarkers in the Diagnosis of Cervical Pre-Cancer and Cancer and Risk Factors in Senegalese.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Nov 2020
Historique:
received: 13 05 2020
entrez: 28 11 2020
pubmed: 29 11 2020
medline: 31 7 2021
Statut: epublish

Résumé

Cervical intraepithelial neoplasia (CIN) grading is subjective and affected by substantial rates of discordance among pathologists. Although recent studies have suggested that p16INK4a may be a useful surrogate biomarker of cervical neoplasia, Ki-67 and human papillomavirus testing have also been shown to be useful in detecting neoplasia. The purpose of this study was to determine the expression of p16INK4a and Ki-67 in cervical neoplasia and its correlations with cofactors. The study involved 69 patients with and without cervical neoplasia who underwent colposcopic directed biopsy. On each patient, two samples were taken; the first was used for immunohistochemistry and the second for molecular testing, using HPV16and18 genotyping Real-Time PCR Kit. The study revealed the expression level of p16INK4a and Ki-67 in a descending order, from invasive squamous cell carcinoma (SCC), CIN2/3, CIN1 and non-dysplastic lesions. Correlations showed an association between the staining of p16NK4a and Ki-67 with the increase of age (OR: 1.79 (95%IC: 0.49 - 6.55), p = 0.037) and marital status (OR: 0.17 (95%IC: 0.04 - 0.68), p = 0.003). We found that the expressions of p16INK4a and Ki-67 were significantly different between invasive SCC vs non-dysplasia (OR: 44.57 (95%IC: 4.91 - 403.91), p <0.0001). The study showed significant correlation between HPV 16and18 infection with p16 INK4a and Ki-67 expression (OR: 0.13 (95%IC: 0.03 - 0.52), p <0.0001). Strong expression of p16INK4a and Ki-67 were observed in invasive squamous cell carcinoma, moderate staining was found in CIN2/3, weak staining in CIN1 and normal histology. Our findings indicate that p16INK4a and Ki-67 expressions associated strongly with cervical pathology. Therefore, p16/Ki-67 could be considered as a suitable biomarker for cervical cancer screening, particularly in HPV-based screening programs.

Sections du résumé

BACKGROUND BACKGROUND
Cervical intraepithelial neoplasia (CIN) grading is subjective and affected by substantial rates of discordance among pathologists. Although recent studies have suggested that p16INK4a may be a useful surrogate biomarker of cervical neoplasia, Ki-67 and human papillomavirus testing have also been shown to be useful in detecting neoplasia. The purpose of this study was to determine the expression of p16INK4a and Ki-67 in cervical neoplasia and its correlations with cofactors.
METHODS METHODS
The study involved 69 patients with and without cervical neoplasia who underwent colposcopic directed biopsy. On each patient, two samples were taken; the first was used for immunohistochemistry and the second for molecular testing, using HPV16and18 genotyping Real-Time PCR Kit.
RESULTS RESULTS
The study revealed the expression level of p16INK4a and Ki-67 in a descending order, from invasive squamous cell carcinoma (SCC), CIN2/3, CIN1 and non-dysplastic lesions. Correlations showed an association between the staining of p16NK4a and Ki-67 with the increase of age (OR: 1.79 (95%IC: 0.49 - 6.55), p = 0.037) and marital status (OR: 0.17 (95%IC: 0.04 - 0.68), p = 0.003). We found that the expressions of p16INK4a and Ki-67 were significantly different between invasive SCC vs non-dysplasia (OR: 44.57 (95%IC: 4.91 - 403.91), p <0.0001). The study showed significant correlation between HPV 16and18 infection with p16 INK4a and Ki-67 expression (OR: 0.13 (95%IC: 0.03 - 0.52), p <0.0001). Strong expression of p16INK4a and Ki-67 were observed in invasive squamous cell carcinoma, moderate staining was found in CIN2/3, weak staining in CIN1 and normal histology.
CONCLUSION CONCLUSIONS
Our findings indicate that p16INK4a and Ki-67 expressions associated strongly with cervical pathology. Therefore, p16/Ki-67 could be considered as a suitable biomarker for cervical cancer screening, particularly in HPV-based screening programs.

Identifiants

pubmed: 33247678
doi: 10.31557/APJCP.2020.21.11.3221
pmc: PMC8033140
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Ki-67 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3221-3227

Références

Cancer Prev Res (Phila). 2020 Feb;13(2):163-172
pubmed: 31871224
J Oncol. 2012;2012:289315
pubmed: 22481919
Malays J Pathol. 2017 Dec;39(3):257-265
pubmed: 29279588
BMC Womens Health. 2016 Jun 04;16:29
pubmed: 27259656
Asian Pac J Cancer Prev. 2016;17(7):3201-6
pubmed: 27509952
Science. 1989 Feb 17;243(4893):934-7
pubmed: 2537532
Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):150-8
pubmed: 23155137
Am J Clin Pathol. 2009 Sep;132(3):378-90
pubmed: 19687314
J Gynecol Oncol. 2008 Sep;19(3):162-8
pubmed: 19471565
J Clin Pathol. 2018 Nov;71(11):981-988
pubmed: 30012698
Asian Pac J Cancer Prev. ;18(10):2643-2647
pubmed: 29072058
Int J Cancer. 2015 Jul 1;137(1):193-203
pubmed: 25471319
Diagn Pathol. 2009 Jul 09;4:22
pubmed: 19589135
J Natl Cancer Inst. 2011 Mar 2;103(5):368-83
pubmed: 21282563
Mod Pathol. 2017 Jul;30(7):1021-1031
pubmed: 28304400
Virol J. 2019 Oct 16;16(1):117
pubmed: 31619262
Indian J Cancer. 2015 Jul-Sep;52(3):270-5
pubmed: 26905107
Oncol Lett. 2016 Feb;11(2):1447-1452
pubmed: 26893758
Gynecol Oncol. 2007 Jan;104(1):207-11
pubmed: 17046054
Implement Sci. 2018 Feb 9;13(1):28
pubmed: 29426344
J Natl Cancer Inst Monogr. 2003;(31):20-8
pubmed: 12807941
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Lancet Public Health. 2018 Jan;3(1):e34-e43
pubmed: 29307386
J Lab Physicians. 2017 Apr-Jun;9(2):104-110
pubmed: 28367025
J Cancer Prev. 2015 Mar;20(1):70-7
pubmed: 25853106
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Dominique Diouf (D)

Laboratory of Cytogenetic and Reproductive Biology, Hospital Aristide-Le-Dantec, Pasteur Avenue, Dakar, Senegal.
Laboratory of Anatomy and Pathology, Principal Military Hospital of Dakar, Nelson Mandela Avenue, Dakar, Senegal.
Cancer Studies and Research Group in Senegal (GERCS), FMPO, Cheikh Anta DIOP University, Cheikh Anta Diop Avenue, Dakar, Senegal.

Gora Diop (G)

Cancer Studies and Research Group in Senegal (GERCS), FMPO, Cheikh Anta DIOP University, Cheikh Anta Diop Avenue, Dakar, Senegal.
Cheikh Anta DIOP University, Department of Animal Biology, Faculty of Science and Technology, Postulant Unit of Genetic, Genomic and Bioinformatic of Infectious Diseases and Cancer, Cheikh Anta Diop Avenue, Dakar, Senegal.
Institut Pasteur Dakar, Pole d'immunophysiopathologie des maladies infectieuses (Pole IMI), Pasteur Avenue, Dakar, Senegal.

Cheikh Fall (C)

Institut Pasteur Dakar, Pole de Virologie, PO Box 220. 36, Pasteur Avenue, Dakar, Senegal.

Souleymane Sarr (S)

Laboratory of Anatomy and Pathology, Principal Military Hospital of Dakar, Nelson Mandela Avenue, Dakar, Senegal.

Cheikh Ahmadou Tidian Diarra (CAT)

Hopital Aristide LeDantec, Service de Cancerologie, Institut-Juliot-Curie, Pasteur Avenue, PO Box 3001, Dakar, Senegal.

Aminata Issa Ngom (AI)

Laboratory of Cytogenetic and Reproductive Biology, Hospital Aristide-Le-Dantec, Pasteur Avenue, Dakar, Senegal.

Sidy Ka (S)

Cancer Studies and Research Group in Senegal (GERCS), FMPO, Cheikh Anta DIOP University, Cheikh Anta Diop Avenue, Dakar, Senegal.
Hopital Aristide LeDantec, Service de Cancerologie, Institut-Juliot-Curie, Pasteur Avenue, PO Box 3001, Dakar, Senegal.

Seynabou Lo (S)

Cancer Studies and Research Group in Senegal (GERCS), FMPO, Cheikh Anta DIOP University, Cheikh Anta Diop Avenue, Dakar, Senegal.

Oumar Faye (O)

Laboratory of Cytogenetic and Reproductive Biology, Hospital Aristide-Le-Dantec, Pasteur Avenue, Dakar, Senegal.
Cancer Studies and Research Group in Senegal (GERCS), FMPO, Cheikh Anta DIOP University, Cheikh Anta Diop Avenue, Dakar, Senegal.

Ahmadou Dem (A)

Cancer Studies and Research Group in Senegal (GERCS), FMPO, Cheikh Anta DIOP University, Cheikh Anta Diop Avenue, Dakar, Senegal.
Hopital Aristide LeDantec, Service de Cancerologie, Institut-Juliot-Curie, Pasteur Avenue, PO Box 3001, Dakar, Senegal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH